{"id":"hydrocortisone-valerate","rwe":[],"_fda":{"id":"a6615fbc-add1-481b-98e0-afd117c7a599","set_id":"17e93b8c-aede-4cab-9a8c-0c29abdb05f2","openfda":{"upc":["0368180954019"],"unii":["68717P8FUZ"],"route":["TOPICAL"],"rxcui":["1370754"],"spl_id":["a6615fbc-add1-481b-98e0-afd117c7a599"],"brand_name":["HYDROCORTISONE VALERATE"],"spl_set_id":["17e93b8c-aede-4cab-9a8c-0c29abdb05f2"],"package_ndc":["68180-954-01","68180-954-02","68180-954-03"],"product_ndc":["68180-954"],"generic_name":["HYDROCORTISONE VALERATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["HYDROCORTISONE VALERATE"],"manufacturer_name":["Lupin Pharmaceuticals, Inc."],"application_number":["ANDA210307"],"is_original_packager":[true]},"version":"7","pregnancy":["Pregnancy Teratogenic Effects Pregnancy Category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Dermal embryofetal developmental studies were conducted in rabbits and rats with hydrocortisone valerate cream, 0.2%. Hydrocortisone valerate cream, 0.2%, was administered topically for 4 hours/day, rather than the preferred 24 hours/day, during the period of organogenesis in rats (gestational days 5 to 16) and rabbits (gestational days 6 to 19). Topical doses of hydrocortisone valerate up to 9 mg/kg/day (54 mg/m 2 /day) were administered to rats and 5 mg/kg/day (60 mg/m 2 /day) were administered to rabbits. In the absence of maternal toxicity, a significant increase in delayed skeletal ossification in fetuses was noted at 9 mg/kg/day [2.5X the Maximum Recommended Human Dose (MRHD) based on body surface area (BSA) comparisons] in the rat study. No malformations in the fetuses were noted at 9 mg/kg/day (2.5X MRHD based on BSA comparisons) in the rat study. Indicators of embryofetal toxicity, significant decrease in fetal weight at 2 mg/kg/day (1X MRHD based on BSA) and a significant increase in post-implantation loss and embryo resorption at 5 mg/kg (3X MRHD based on BSA), were noted in the rabbit study. A significant increase in delayed skeletal ossification in fetuses was noted at 5 mg/kg/day (3X the MRHD based on BSA comparisons) in the rabbit study.Increased numbers of fetal malformations (e.g., cleft palate, omphalocele and clubbed feet) were noted at 5 mg/kg/day (3X MRHD based on BSA comparisons) in the rabbit study. There are no adequate and well-controlled studies in pregnant women. Hydrocortisone valerate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE Topically applied hydrocortisone valerate cream can be absorbed in sufficient amounts to produce systemic effects ( see PRECAUTIONS )."],"description":["DESCRIPTION Hydrocortisone valerate cream USP contain hydrocortisone valerate, 11β,17,21-Trihydroxypregn-4-ene-3,20-dione 17-Valerate, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, hydrocortisone valerate is C 26 H 38 O 6 . It has the following structural formula: Hydrocortisone valerate has a molecular weight of 446.58. It is a white to off-white crystalline powder, soluble in ethanol and methanol, sparingly soluble in propylene glycol and insoluble in water. Each gram of hydrocortisone valerate cream USP contains 2 mg hydrocortisone valerate USP in a hydrophilic base composed of carbomer homopolymer type C, dibasic sodium phosphate, methylparaben, polyoxyl 2 stearyl ether, propylene glycol, purified water, sodium lauryl sulfate, steareth-100, stearyl alcohol and white petrolatum. Hydrocortisone Valerate"],"precautions":["PRECAUTIONS General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Hydrocortisone valerate cream has produced mild, reversible adrenal suppression in adult patients when used under occlusion for 5 days, 15 grams twice a day over 25 to 60% body surface area or when used three times a day over 20 to 30% body surface area to treat psoriasis for 3 to 4 weeks. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for these products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios ( see PRECAUTIONS - Pediatric Use ). If irritation develops, hydrocortisone valerate cream should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of hydrocortisone valerate cream should be discontinued until the infection has been adequately controlled. Information for Patients Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. This medication should not be used for any disorder other than that for which it was prescribed. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician. Patients should report to their physician any signs of local adverse reactions. Hydrocortisone valerate cream should not be applied in the diaper areas as diapers or plastic pants may constitute occlusive dressings ( see DOSAGE AND ADMINISTRATION ). This medication should not be used on the face, underarms, or groin areas unless directed by the physician. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician. Laboratory Tests The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test A.M. plasma cortisol test Urinary free cortisol test Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of hydrocortisone valerate. Hydrocortisone valerate cream was shown to be non-mutagenic in the Ames-Salmonella/Microsome Plate Test. There are no studies which assess the effects of hydrocortisone valerate on fertility and general reproductive performance. Pregnancy Teratogenic Effects Pregnancy Category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Dermal embryofetal developmental studies were conducted in rabbits and rats with hydrocortisone valerate cream, 0.2%. Hydrocortisone valerate cream, 0.2%, was administered topically for 4 hours/day, rather than the preferred 24 hours/day, during the period of organogenesis in rats (gestational days 5 to 16) and rabbits (gestational days 6 to 19). Topical doses of hydrocortisone valerate up to 9 mg/kg/day (54 mg/m 2 /day) were administered to rats and 5 mg/kg/day (60 mg/m 2 /day) were administered to rabbits. In the absence of maternal toxicity, a significant increase in delayed skeletal ossification in fetuses was noted at 9 mg/kg/day [2.5X the Maximum Recommended Human Dose (MRHD) based on body surface area (BSA) comparisons] in the rat study. No malformations in the fetuses were noted at 9 mg/kg/day (2.5X MRHD based on BSA comparisons) in the rat study. Indicators of embryofetal toxicity, significant decrease in fetal weight at 2 mg/kg/day (1X MRHD based on BSA) and a significant increase in post-implantation loss and embryo resorption at 5 mg/kg (3X MRHD based on BSA), were noted in the rabbit study. A significant increase in delayed skeletal ossification in fetuses was noted at 5 mg/kg/day (3X the MRHD based on BSA comparisons) in the rabbit study.Increased numbers of fetal malformations (e.g., cleft palate, omphalocele and clubbed feet) were noted at 5 mg/kg/day (3X MRHD based on BSA comparisons) in the rabbit study. There are no adequate and well-controlled studies in pregnant women. Hydrocortisone valerate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when hydrocortisone valerate cream USP, 0.2% is administered to a nursing woman. Pediatric Use Safety of this product in pediatric patients has not been established. There is no data on adrenal suppression and/or growth suppression. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at a greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children ( see PRECAUTIONS ). HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Geriatric Use Clinical studies of hydrocortisone valerate cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients."],"how_supplied":["HOW SUPPLIED Hydrocortisone valerate cream USP, 0.2%, is supplied in 15 g (NDC 68180-954-01), 45 g (NDC 68180-954-02) and 60 g (NDC 68180-954-03) tube sizes. Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc. Image"],"geriatric_use":["Geriatric Use Clinical studies of hydrocortisone valerate cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients."],"pediatric_use":["Pediatric Use Safety of this product in pediatric patients has not been established. There is no data on adrenal suppression and/or growth suppression. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at a greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children ( see PRECAUTIONS ). HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema."],"effective_time":"20251113","nursing_mothers":["Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when hydrocortisone valerate cream USP, 0.2% is administered to a nursing woman."],"laboratory_tests":["Laboratory Tests The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test A.M. plasma cortisol test Urinary free cortisol test"],"pharmacokinetics":["Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Studies performed with hydrocortisone valerate cream indicate that it is in the medium range of potency as compared with other topical corticosteroids."],"adverse_reactions":["ADVERSE REACTIONS The following local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies involving pediatric patients one month to 2 years of age (n=29), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream, was approximately 21%. Reported reactions included stinging (10%), eczema (7%), fungal infection (3%), and gastrointestinal disorder (3%). In controlled clinical studies involving pediatric patients 2 to 12 years of age (n=153), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream, was approximately 10%. Reported reactions included stinging (3%), burning skin (2%), infection (Body as a Whole) (2%). Skin irritation, eczema, pruritus, application site reaction, rash, rash maculopapular, and dry skin were all reported at incidences of approximately 1%."],"contraindications":["CONTRAINDICATIONS Hydrocortisone valerate cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Like other topical corticosteroids, hydrocortisone valerate has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Studies performed with hydrocortisone valerate cream indicate that it is in the medium range of potency as compared with other topical corticosteroids."],"indications_and_usage":["INDICATIONS AND USAGE Hydrocortisone valerate cream USP is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients."],"information_for_patients":["Information for Patients Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. This medication should not be used for any disorder other than that for which it was prescribed. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician. Patients should report to their physician any signs of local adverse reactions. Hydrocortisone valerate cream should not be applied in the diaper areas as diapers or plastic pants may constitute occlusive dressings ( see DOSAGE AND ADMINISTRATION ). This medication should not be used on the face, underarms, or groin areas unless directed by the physician. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician."],"spl_unclassified_section":["Rx only For Dermatologic Use Only. Not for Ophthalmic Use.","Manufactured for: Lupin Pharmaceuticals, Inc. , Naples, FL 34108 United States. Manufactured by: Lupin Limited , Pithampur (M.P.) - 454 775, India. December 2024 ID: 278158"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Hydrocortisone valerate cream should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Hydrocortisone valerate cream should not be used with occlusive dressings unless directed by a physician. Hydrocortisone valerate cream should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing."],"spl_product_data_elements":["HYDROCORTISONE VALERATE HYDROCORTISONE VALERATE HYDROCORTISONE VALERATE HYDROCORTISONE CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) SODIUM PHOSPHATE, DIBASIC, ANHYDROUS METHYLPARABEN STEARETH-2 PROPYLENE GLYCOL WATER SODIUM LAURYL SULFATE STEARETH-100 STEARYL ALCOHOL PETROLATUM White to off-white"],"package_label_principal_display_panel":["Hydrocortisone Valerate Cream USP, 0.2% 15 g NDC 68180-954-01 Rx only FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC USE. Keep this and all medications out of the reach of children. Hydrocortisone Valerate Cream USP, 0.2% 15 g Tube label NDC 68180-954-01 Rx only Hydrocortisone Valerate Cream USP, 0.2% 15 g Carton label NDC 68180-954-01 Rx only"]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Ointment","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Sun Pharm Inds Inc","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"142 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"55 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"54 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"51 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"51 reports"},{"date":"","signal":"WEIGHT DECREASED","source":"FDA FAERS","actionTaken":"51 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"PSORIASIS","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"48 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"44 reports"}],"commonSideEffects":[{"effect":"Worsening of condition","drugRate":"2%","severity":"common","_validated":true},{"effect":"Transient itching","drugRate":"2%","severity":"common","_validated":true},{"effect":"Irritation","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Redness","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Eczema","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pruritis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Stinging","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Dry skin","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Burning","drugRate":"reported","severity":"unknown"},{"effect":"Dryness","drugRate":"reported","severity":"unknown"},{"effect":"Folliculitis","drugRate":"reported","severity":"unknown"},{"effect":"Acneiform eruptions","drugRate":"reported","severity":"unknown"},{"effect":"Hypopigmentation","drugRate":"reported","severity":"unknown"},{"effect":"Perioral dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"Allergic contact dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"Secondary infection","drugRate":"reported","severity":"unknown"},{"effect":"Skin atrophy","drugRate":"reported","severity":"unknown"},{"effect":"Striae","drugRate":"reported","severity":"unknown"},{"effect":"Miliaria","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.Dermal embryofetal developmental studies were conducted in rabbits and rats with hydrocortisone valerate cream, 0.2%. Hydrocortisone valerate cream, 0.2%, was administered topically for hours/day, rather than continuously for 24 hours/day.","Geriatric use":"Clinical studies of hydrocortisone valerate ointment, 0.2% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.","Paediatric use":"Because of higher ratio of skin surface area to body mass, pediatric patients are at greater risk than adults of HPA axis suppression and Cushings syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects including striae, impaired growth, and glaucoma have been reported in pediatric patients."}},"trials":[],"aliases":[],"company":"Sun Pharma","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0535/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$20","description":"HYDROCORTISONE 0.5% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HYDROCORTISONE VALERATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:05:28.953116+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:06:02.415325+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:05:41.105568+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:05:27.578690+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYDROCORTISONE VALERATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:05:42.406120+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:05:26.055784+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:05:52.928803+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:05:26.055841+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:05:43.964586+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:05:43.010115+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200562/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:05:42.917362+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA210307","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:05:26.055851+00:00"}},"allNames":"westcort","offLabel":[],"synonyms":["hydrocortisone valerate","hydrocortisone pentanoate"],"timeline":[{"date":"1978-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from RANBAXY to Sun Pharm Inds Inc"},{"date":"1978-03-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Ranbaxy)"},{"date":"1983-08-08","type":"positive","source":"FDA Orange Book","milestone":"Westcort approved — 0.2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1998-08-12","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Hydrocortisone Valerate (Westcort), marketed by Sun Pharma, is a corticosteroid indicated for corticosteroid-responsive dermatoses, competing in a segment with several off-patent generics such as alclometasone dipropionate and amcinonide. Its key strength lies in its mechanism of action through the glucocorticoid receptor, which effectively triggers anti-inflammatory responses, potentially offering a differentiated efficacy profile. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased generic competition and revenue erosion.","approvals":[{"date":"1978-03-17","orphan":false,"company":"RANBAXY","regulator":"FDA"}],"brandName":"Westcort","ecosystem":[],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"","oneSentence":"","technicalDetail":"Westcort (HYDROCORTISONE VALERATE) is a small molecule corticosteroid that exerts its effects by binding to the glucocorticoid receptor (GR), a transcription factor that regulates the expression of genes involved in inflammation and immune response. This binding event triggers a cascade of downstream effects, including the inhibition of pro-inflammatory cytokines and the induction of anti-inflammatory genes, ultimately leading to the reduction of inflammation and skin symptoms."},"commercial":{"launchDate":"1978","_launchSource":"DrugCentral (FDA 1978-03-17, RANBAXY)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4504","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HYDROCORTISONE%20VALERATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYDROCORTISONE VALERATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:56:57.608063","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:06:02.415469+00:00","fieldsConflicting":3,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alclometasone dipropionate","drugSlug":"alclometasone-dipropionate","fdaApproval":"1982-12-14","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amcinonide","drugSlug":"amcinonide","fdaApproval":"1979-10-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"auranofin","drugSlug":"auranofin","fdaApproval":"1985-05-24","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-target"},{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone acetate","drugSlug":"betamethasone-acetate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone benzoate","drugSlug":"betamethasone-benzoate","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone dipropionate","drugSlug":"betamethasone-dipropionate","fdaApproval":"1975-01-29","patentExpiry":"Aug 31, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"betamethasone phosphate","drugSlug":"betamethasone-phosphate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone valerate","drugSlug":"betamethasone-valerate","fdaApproval":"1967-09-02","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"},{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"hydrocortisone valerate","indications":{"approved":[{"id":"hydrocortisone-valerate-corticosteroid-responsive-derm","name":"Corticosteroid-responsive dermatoses","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients","diagnosticRequired":null,"brandNameForIndication":"Westcort"}],"offLabel":[],"pipeline":[]},"currentOwner":"Sun Pharm Inds Inc","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"alclometasone-dipropionate","brandName":"alclometasone dipropionate","genericName":"alclometasone dipropionate","approvalYear":"1982","relationship":"same-target"},{"drugId":"amcinonide","brandName":"amcinonide","genericName":"amcinonide","approvalYear":"1979","relationship":"same-target"},{"drugId":"auranofin","brandName":"auranofin","genericName":"auranofin","approvalYear":"1985","relationship":"same-target"},{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-target"},{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-target"},{"drugId":"betamethasone-acetate","brandName":"betamethasone acetate","genericName":"betamethasone acetate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-benzoate","brandName":"betamethasone benzoate","genericName":"betamethasone benzoate","approvalYear":"","relationship":"same-target"},{"drugId":"betamethasone-dipropionate","brandName":"betamethasone dipropionate","genericName":"betamethasone dipropionate","approvalYear":"1975","relationship":"same-target"},{"drugId":"betamethasone-phosphate","brandName":"betamethasone phosphate","genericName":"betamethasone phosphate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-valerate","brandName":"betamethasone valerate","genericName":"betamethasone valerate","approvalYear":"1967","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":["Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":244,"completionDate":"2026-12-31"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":["Shift Work Schedule","Circadian Rhythm","Insulin Resistance","Circadian Misalignment"],"enrollment":24,"completionDate":"2029-07"},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":["Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8"],"enrollment":1875,"completionDate":"2031-04-28"},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Childhood Acute Lymphoblastic Leukemia","Childhood Acute Myeloid Leukemia","Childhood Mixed Phenotype Acute Leukemia","Mixed Phenotype Acute Leukemia"],"enrollment":29,"completionDate":"2028-11-12"},{"nctId":"NCT07033039","phase":"NA","title":"Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2026-01-30","conditions":["Rhinoplasty","Edema"],"enrollment":60,"completionDate":"2030-11-30"},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)","Prostatic Neoplasms"],"enrollment":1314,"completionDate":"2030-12-02"},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":["Prostate Cancer Metastatic"],"enrollment":1310,"completionDate":"2028-08-02"},{"nctId":"NCT04924166","phase":"PHASE2","title":"PTSD Prevention Using Oral Hydrocortisone","status":"COMPLETED","sponsor":"Rachel Yehuda","startDate":"2022-01-12","conditions":["PTSD","Acute Stress Disorder","Trauma-related Stressor"],"enrollment":201,"completionDate":"2025-07-06"},{"nctId":"NCT06136598","phase":"PHASE1","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-30","conditions":["Prostatic Neoplasms","Metastatic Castration-Resistant Prostate Cancer"],"enrollment":14,"completionDate":"2026-03-09"},{"nctId":"NCT06892197","phase":"PHASE4","title":"Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)","status":"RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2026-03-10","conditions":["Community Acquired Pneumonia (CAP)"],"enrollment":1600,"completionDate":"2030-11-01"},{"nctId":"NCT06892210","phase":"PHASE4","title":"Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)","status":"RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2026-03-10","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":2000,"completionDate":"2030-11-01"},{"nctId":"NCT05423613","phase":"NA","title":"Microneedling for Burn Hypertrophic Scars","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-01-22","conditions":["Burn Scar"],"enrollment":36,"completionDate":"2026-07-31"},{"nctId":"NCT05435781","phase":"PHASE4","title":"Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency","status":"RECRUITING","sponsor":"Marianne Christina Klose","startDate":"2022-06-07","conditions":["Adrenal Insufficiency","Polymyalgia Rheumatica","Giant Cell Arteritis"],"enrollment":250,"completionDate":"2028-03-01"},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":222,"completionDate":"2030-12-01"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT06504160","phase":"PHASE1","title":"Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-10","conditions":["Atopic Dermatitis"],"enrollment":86,"completionDate":"2027-02-05"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":["Malignant Neoplasm"],"enrollment":250,"completionDate":"2027-11-04"},{"nctId":"NCT06104449","phase":"PHASE1","title":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-14","conditions":["Prostatic Neoplasms","Metastatic Castration-Resistant Prostate Cancer"],"enrollment":6,"completionDate":"2026-04-20"},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":["Acute Aluminum Phosphide Poisoned Cases"],"enrollment":74,"completionDate":"2027-03"},{"nctId":"NCT07451886","phase":"PHASE2","title":"Adjunctive Fludrocortisone in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-04-01","conditions":["Sepsis","Septic Shock","Sepsis - to Reduce Mortality in the Intensive Care Unit","Sepsis and Septic Shock","Sepsis at Intensive Care Unit"],"enrollment":32,"completionDate":"2028-07-31"},{"nctId":"NCT06177067","phase":"PHASE1","title":"Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-04-19","conditions":["Refractory Acute Myeloid Leukemia","Relapsed Acute Myeloid Leukemia","Acute Leukemia of Ambiguous Lineage"],"enrollment":24,"completionDate":"2027-04"},{"nctId":"NCT07383103","phase":"PHASE4","title":"Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2026-03-02","conditions":["Septic Shock"],"enrollment":336,"completionDate":"2028-12-31"},{"nctId":"NCT06556277","phase":"NA","title":"Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake","status":"COMPLETED","sponsor":"Eleonora Seelig","startDate":"2024-09-01","conditions":["Glucocorticoids","Overweight and Obesity","Overeating"],"enrollment":23,"completionDate":"2026-02-25"},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma","Mixed Phenotype Acute Leukemia"],"enrollment":850,"completionDate":"2039-05"},{"nctId":"NCT03742414","phase":"PHASE2","title":"Seal, Stopping Eczema and Allergy Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kari Nadeau, MD, PhD","startDate":"2021-06-30","conditions":["Eczema, Infantile","Eczema","Atopic Dermatitis Eczema","Atopic Dermatitis"],"enrollment":398,"completionDate":"2028-06-30"},{"nctId":"NCT06078696","phase":"PHASE1,PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":["Anemia, Sickle Cell"],"enrollment":1,"completionDate":"2025-12-11"},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":["T-cell Acute Lymphoblastic Leukemia","T-cell Lymphoma","Mixed Phenotype Acute Leukemia"],"enrollment":100,"completionDate":"2033-12"},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":["CNS Embryonal Tumor","CNS, Medulloblastoma","Atypical Teratoid Rhabdoid Tumor","Medulloblastoma, Childhood","Medulloblastoma, Group 3","Medulloblastoma, Group 4","Pineoblastoma","Neuroblastoma","Embryonal Tumor With Multilayered Rosettes","Embryonal Tumor With Abundant Neuropil and True Rosettes","Ependymoblastoma","Medulloepithelioma","CNS Embryonal Tumor With Rhabdoid Features","CNS Embryonal Tumor, Nos"],"enrollment":15,"completionDate":"2032-12-31"},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":["Acute Myeloid Leukemia"],"enrollment":1186,"completionDate":"2029-06-30"},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":["Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Myelodysplastic Syndrome","Recurrent Juvenile Myelomonocytic Leukemia","Refractory Childhood Acute Myeloid Leukemia","Refractory Childhood Myelodysplastic Syndrome","Refractory Juvenile Myelomonocytic Leukemia"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT05451264","phase":"NA","title":"Study of the Effect of Hydrocortisone Administered for the Prevention of Pulmonary Bronchodysplasia (PREMILOC Trial) on the Determinants of Systemic Blood Pressure in Children (PREMILOCAP)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-01-23","conditions":["Infant, Premature, Diseases"],"enrollment":52,"completionDate":"2024-07-11"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":["Respiratory Insufficiency","Extracorporeal Membrane Oxygenation Complication","Mechanical Ventilation Pressure High"],"enrollment":6250,"completionDate":"2027-03-31"},{"nctId":"NCT05436535","phase":"PHASE4","title":"Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-11-21","conditions":["Atopic Dermatitis"],"enrollment":433,"completionDate":"2025-10-24"},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":["Mild Cognitive Impairment","Dementia, Mild"],"enrollment":73,"completionDate":"2026-02-09"},{"nctId":"NCT05160506","phase":"PHASE2","title":"Corticosteroids to Treat Pancreatitis","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2022-03-06","conditions":["Pancreatitis","Pancreatitis, Acute","Corticosteroid","Hydrocortisone"],"enrollment":86,"completionDate":"2027-04"},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":["Drug/Agent Toxicity by Tissue/Organ","Leukemia"],"enrollment":800,"completionDate":"2019-06"},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":128,"completionDate":"2034-05"},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":5,"completionDate":"2025-09-15"},{"nctId":"NCT05299554","phase":"PHASE3","title":"Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2022-04-01","conditions":["Congenital Adrenal Hyperplasia"],"enrollment":76,"completionDate":"2026-01-15"},{"nctId":"NCT07387926","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-26","conditions":["Acute Lymphoblastic Leukemia","Leukemia, Lymphoblastic, Acute, Philadelphia-Positive","Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2035-12-12"},{"nctId":"NCT05656248","phase":"PHASE2","title":"Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-01-17","conditions":["Myeloid Neoplasm"],"enrollment":25,"completionDate":"2028-08"},{"nctId":"NCT06895473","phase":"PHASE2","title":"Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-04","conditions":["Hematopoietic and Lymphatic System Neoplasm"],"enrollment":26,"completionDate":"2027-12-31"},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":206,"completionDate":"2027-06"},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":["Sepsis"],"enrollment":2000,"completionDate":"2031-05-01"},{"nctId":"NCT04898894","phase":"PHASE1","title":"Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-11-15","conditions":["Acute Leukemia of Ambiguous Lineage in Relapse","Acute Myeloid Leukemia, in Relapse","Refractory Acute Leukemia of Ambiguous Lineage","Refractory Acute Myeloid Leukemia"],"enrollment":37,"completionDate":"2027-09"},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":["Acute Lymphoblastic Leukemia, Pediatric"],"enrollment":560,"completionDate":"2034-11"},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":["Immunodeficiencies","Primary Immunodeficiencies (PID)","Agammaglobulinemia"],"enrollment":50,"completionDate":"2027-02-27"},{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":["Sepsis","Tuberculosis"],"enrollment":344,"completionDate":"2029-09"},{"nctId":"NCT04943289","phase":"PHASE1","title":"Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Joanne Kurtzberg, MD","startDate":"2021-01-24","conditions":["Primary Progressive Multiple Sclerosis"],"enrollment":20,"completionDate":"2025-09-30"},{"nctId":"NCT06217939","phase":"NA","title":"Early Intravenous Hydrocortisone in Sepsis","status":"RECRUITING","sponsor":"Siriraj Hospital","startDate":"2024-06-25","conditions":["Sepsis Severe","Shock, Septic"],"enrollment":230,"completionDate":"2026-09"},{"nctId":"NCT07313670","phase":"NA","title":"Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Muhammad Aamir Latif","startDate":"2026-01-01","conditions":["Septic Shock"],"enrollment":122,"completionDate":"2026-06-30"},{"nctId":"NCT07072585","phase":"PHASE2,PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":["Stage II T Lymphoblastic Leukemia/Lymphoma","Stage III T Lymphoblastic Leukemia/Lymphoma","Stage IV T Lymphoblastic Leukemia/Lymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1708,"completionDate":"2035-09-01"},{"nctId":"NCT04231708","phase":"PHASE2","title":"Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Wayne State University","startDate":"2026-10","conditions":["Opioid Use Disorder"],"enrollment":20,"completionDate":"2028-12"},{"nctId":"NCT06842316","phase":"","title":"Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2025-04-10","conditions":["Inflammatory Disorder of Immune System","Spondylitis, Ankylosing","Arthritis, Rheumatoid","Arthritis, Psoriatic","Inflammatory Bowel Diseases","Sjogren's Syndrome","Lupus Erythematosus, Systemic"],"enrollment":100,"completionDate":"2027-04-09"},{"nctId":"NCT00097474","phase":"PHASE2","title":"Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-12-21","conditions":["Jet Lag"],"enrollment":57,"completionDate":"2007-11-14"},{"nctId":"NCT03568318","phase":"PHASE3","title":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-09","conditions":["Atopic Dermatitis"],"enrollment":1533,"completionDate":"2030-10-23"},{"nctId":"NCT05193396","phase":"PHASE4","title":"Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment","status":"RECRUITING","sponsor":"Marianne Andersen","startDate":"2022-02-01","conditions":["Adrenal Insufficiency","Polymyalgia Rheumatica (PMR)","Giant Cell Arteritis (GCA)"],"enrollment":100,"completionDate":"2026-01"},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":["Recurrent Acute Leukemia of Ambiguous Lineage","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Refractory Acute Leukemia of Ambiguous Lineage","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Refractory Mixed Phenotype Acute Leukemia"],"enrollment":78,"completionDate":"2027-12-31"},{"nctId":"NCT02517489","phase":"PHASE3","title":"Community-Acquired Pneumonia : Evaluation of Corticosteroids","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2015-10-28","conditions":["Community Acquired Pneumonia"],"enrollment":952,"completionDate":"2020-08-28"},{"nctId":"NCT07262957","phase":"PHASE4","title":"Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-09-01","conditions":["Pancreas Head Cancer","Pancreas Adenocarcinoma","IPMN, Pancreatic","Cholangio Carcinoma","Ampulla of Vater Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Duodenal Carcinoma","Mucinous Cystic Neoplasm","Neuro Endocrine Tumours","Pancreatitis"],"enrollment":400,"completionDate":"2027-12-01"},{"nctId":"NCT03896659","phase":"PHASE4","title":"Exploring the Effects of Corticosteroids on the Human Hippocampus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-10-01","conditions":["Hydrocortisone","Depression","Healthy Volunteers"],"enrollment":66,"completionDate":"2024-09-16"},{"nctId":"NCT06409364","phase":"PHASE2","title":"FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-08-13","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":524,"completionDate":"2030-07-31"},{"nctId":"NCT02553460","phase":"PHASE1,PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2031-10"},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":["Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":669,"completionDate":"2026-09-16"},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":["Adult T Acute Lymphoblastic Leukemia","Ann Arbor Stage II Adult Lymphoblastic Lymphoma","Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","Ann Arbor Stage III Adult Lymphoblastic Lymphoma","Ann Arbor Stage III Childhood Lymphoblastic Lymphoma","Ann Arbor Stage IV Adult Lymphoblastic Lymphoma","Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma","Childhood T Acute Lymphoblastic Leukemia"],"enrollment":847,"completionDate":"2026-09-16"},{"nctId":"NCT02997605","phase":"PHASE4","title":"Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-01-31","conditions":["RheumatoId Arthritis"],"enrollment":102,"completionDate":"2022-01-27"},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Central Nervous System Leukemia","Testicular Leukemia"],"enrollment":5949,"completionDate":"2026-10-03"},{"nctId":"NCT05354778","phase":"NA","title":"HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study","status":"RECRUITING","sponsor":"Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo","startDate":"2022-10-16","conditions":["Healthcare-Associated Pneumonia","Ventilator Associated Pneumonia"],"enrollment":180,"completionDate":"2027-02"},{"nctId":"NCT07248761","phase":"PHASE4","title":"Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2025-02-01","conditions":["Shock","Preterm Birth Complication","Preterm Intraventricular Hemorrhage","Asphyxia Perinatal","Distress Respiratory Syndrome","Hyperglycaemia (Non Diabetic)","Neonatal Sepsis, Early-Onset","Neonatal Sepsis, Late-Onset","NEC - Necrotizing Enterocolitis","Patent Ductus Arteriosus in Preterm Infants","Intestinal Perforation"],"enrollment":76,"completionDate":"2026-07-30"},{"nctId":"NCT02473263","phase":"PHASE3","title":"Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-09","conditions":["Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit"],"enrollment":398,"completionDate":"2019-02-09"},{"nctId":"NCT02252237","phase":"","title":"Pharmacokinetics of Glucocorticoids in Children (GLUCOPED)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-12-03","conditions":["Children Receiving Prednisone or Prednisolone or Methylprednisolone or Hydrocortisone"],"enrollment":146,"completionDate":"2021-12-09"},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":["Sepsis and Septic Shock","Acute Respiratory Failure","Kidney Transplant Recipients","Immunosuppressive Agents"],"enrollment":212,"completionDate":"2029-06-01"},{"nctId":"NCT02574910","phase":"PHASE1","title":"Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-08-01","conditions":["Congenital Adrenal Hyperplasia"],"enrollment":4,"completionDate":"2023-06-03"},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":["Acute Myeloid Leukemia","Pediatric AML"],"enrollment":36,"completionDate":"2031-08"},{"nctId":"NCT04456439","phase":"","title":"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast International Sàrl","startDate":"","conditions":["Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)"],"enrollment":0,"completionDate":""},{"nctId":"NCT03401398","phase":"PHASE3","title":"Stress Hydrocortisone In Pediatric Septic Shock","status":"RECRUITING","sponsor":"Jerry Zimmerman","startDate":"2019-03-11","conditions":["Septic Shock"],"enrollment":500,"completionDate":"2026-12-31"},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":["Covid19"],"enrollment":473,"completionDate":"2022-11-20"},{"nctId":"NCT00136435","phase":"PHASE2","title":"A Study in Adults With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2002-06","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":100,"completionDate":"2011-05"},{"nctId":"NCT06729593","phase":"PHASE3","title":"Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":["Covid19"],"enrollment":87,"completionDate":"2022-11-20"},{"nctId":"NCT06729606","phase":"PHASE3","title":"Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":["Covid19"],"enrollment":471,"completionDate":"2022-11-20"},{"nctId":"NCT04082533","phase":"PHASE4","title":"Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-24","conditions":["Pain","Arthrofibrosis","Osteoarthritis, Knee"],"enrollment":132,"completionDate":"2026-05"},{"nctId":"NCT05974410","phase":"","title":"Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients","status":"AVAILABLE","sponsor":"AVM Biotechnology Inc","startDate":"","conditions":["Glioblastoma","Squamous Cell Carcinoma","Hodgkin Lymphoma","Non-hodgkin Lymphoma","Breast Cancer","Prostate Cancer","Gastric Cancer","Ovarian Cancer","Acute Leukemia","Pancreatic Cancer","Spindle Cell Sarcoma","Cancer","Tumor, Solid","Tumor, Brain","Esophageal Andeocarcinoma","Mixed Phenotype AML","Desmoplastic Round Cell Sarcoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT04501614","phase":"PHASE1,PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":["Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)","Ph+ Mixed Phenotype Acute Leukemia (MPAL)","Philadelphia Chromosome-Like ALL (Ph-like ALL)"],"enrollment":11,"completionDate":"2024-07-19"},{"nctId":"NCT04280497","phase":"NA","title":"Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-10","conditions":["Sepsis"],"enrollment":1800,"completionDate":"2025-12"},{"nctId":"NCT04479267","phase":"PHASE2","title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2020-08-21","conditions":["Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements","Double Expressor Lymphoma","High-grade B-cell Lymphoma"],"enrollment":8,"completionDate":"2026-07-19"},{"nctId":"NCT07124650","phase":"PHASE4","title":"Sore Throat After Open Neck Elective Surgery","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2025-09-15","conditions":["Postoperative Sore Throat, Cough, Hoarseness","Thyroid and Parathyroid Surgery"],"enrollment":764,"completionDate":"2027-05"},{"nctId":"NCT05192889","phase":"PHASE1,PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":["Refractory Acute Lymphoblastic Leukemia","Relapsed Acute Lymphoblastic Leukemia"],"enrollment":35,"completionDate":"2027-02"},{"nctId":"NCT05745714","phase":"PHASE1,PHASE2","title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":["Acute Lymphoblastic Leukemia, in Relapse","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory"],"enrollment":26,"completionDate":"2032-02-02"},{"nctId":"NCT07175415","phase":"PHASE1,PHASE2","title":"HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2026-10-01","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory"],"enrollment":42,"completionDate":"2032-10-01"},{"nctId":"NCT05658640","phase":"PHASE1,PHASE2","title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-11-14","conditions":["Acute Lymphoblastic Leukemia, in Relapse","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory"],"enrollment":26,"completionDate":"2029-04-01"},{"nctId":"NCT06430580","phase":"EARLY_PHASE1","title":"Cannabinoids and Biological Reactivity to Stress","status":"RECRUITING","sponsor":"Florida State University","startDate":"2024-09-30","conditions":["Cannabis Use Disorder"],"enrollment":36,"completionDate":"2026-09-30"},{"nctId":"NCT03760835","phase":"PHASE4","title":"Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment","status":"RECRUITING","sponsor":"Federico II University","startDate":"2016-08-11","conditions":["Congenital Adrenal Hyperplasia"],"enrollment":150,"completionDate":"2027-12-31"},{"nctId":"NCT05751044","phase":"PHASE1,PHASE2","title":"HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory"],"enrollment":26,"completionDate":"2032-02-01"},{"nctId":"NCT04037605","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-02-09","conditions":["Sleep Restriction"],"enrollment":5,"completionDate":"2026-06-24"},{"nctId":"NCT06649409","phase":"PHASE1","title":"Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2024-06-05","conditions":["Pharmacodynamic"],"enrollment":30,"completionDate":"2024-07-06"},{"nctId":"NCT03142893","phase":"PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter y. Liu","startDate":"2017-05-08","conditions":["Sleep Restriction"],"enrollment":80,"completionDate":"2026-06-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cream, Ointment","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"HYDROCORTISONE VALERATE"},{"form":"CREAM","route":"TOPICAL","productName":"Hydrocortisone Valerate"},{"form":"CREAM","route":"TOPICAL","productName":"Hydrocortisone valerate"},{"form":"CREAM","route":"TOPICAL","productName":"hydrocortisone valerate cream"},{"form":"OINTMENT","route":"TOPICAL","productName":"Hydrocortisone Valerate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000179155","MMSL":"11849","NDDF":"002147","UNII":"68717P8FUZ","VUID":"4017946","CHEBI":"CHEBI:50865","VANDF":"4017941","INN_ID":"38","RXNORM":"27199","UMLSCUI":"C0063079","chemblId":"CHEMBL1200562","ChEMBL_ID":"CHEMBL1200562","KEGG_DRUG":"D02288","DRUGBANK_ID":"DB14544","PUBCHEM_CID":"5282494","SNOMEDCT_US":"16602005","MESH_DESCRIPTOR_UI":"D006854","MESH_SUPPLEMENTAL_RECORD_UI":"C038363"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1978-","companyName":"Ranbaxy","relationship":"Original Developer"},{"period":"present","companyName":"Sun Pharm Inds Inc","relationship":"Current Owner"}],"publicationCount":11,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Ranbaxy","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":7,"_genericFilersChecked":true,"genericManufacturerList":["Cosette","Encube Ethicals","Fougera Pharms","Glenmark Pharms Ltd","Lupin Ltd","Padagis Israel","Sun Pharma Canada"],"status":"approved","companyName":"Sun Pharm Inds Inc","companyId":"sun-pharma","modality":"Small molecule","firstApprovalDate":"1978","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1978-03-17T00:00:00.000Z","mah":"RANBAXY","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1978-03-17T00:00:00.000Z","mah":"RANBAXY","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1978-03-17T00:00:00.000Z","mah":"RANBAXY","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1978-03-17T00:00:00.000Z","mah":"RANBAXY","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1978-03-17T00:00:00.000Z","mah":"RANBAXY","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1978-03-17T00:00:00.000Z","mah":"RANBAXY","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-12-14T00:00:00.000Z","mah":"GLENMARK PHARMS LTD","brand_name_local":null,"application_number":"ANDA211750"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-08-15T00:00:00.000Z","mah":"LUPIN LTD","brand_name_local":null,"application_number":"ANDA210307"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-03-04T00:00:00.000Z","mah":"COSETTE","brand_name_local":null,"application_number":"ANDA211764"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-02-11T00:00:00.000Z","mah":"COSETTE","brand_name_local":null,"application_number":"ANDA213724"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-11-04T00:00:00.000Z","mah":"ENCUBE ETHICALS","brand_name_local":null,"application_number":"ANDA211047"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:06:02.415469+00:00","fieldsConflicting":3,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}